COMPANY PROFILE

Precision Biologics

Explore full profile

Cancer immunotherapy platform with 2 unique clinical stage monoclonal antibodies

Bethesda, United StatesFounded 2012Biotech & Life Sciences

Valuation $250–500M Last recorded · 2015

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Precision Biologics

Precision Biologics is a pioneering company in the biotherapeutics and diagnostics sector, dedicated to improving the lives of cancer patients through innovative products. The company specializes in developing targeted monoclonal antibodies designed to attack tumors without harming healthy cells. Operating primarily in the oncology market, Precision Biologics serves healthcare providers and research institutions focused on cancer treatment and diagnostics. The business model revolves around the development and clinical trials of its proprietary antibodies, which are then licensed to pharmaceutical companies or sold directly to healthcare providers. Revenue is generated through licensing fees, sales of therapeutic products, and partnerships with other biotech firms. The company is currently advancing its first monoclonal antibody, NEO 102, through Phase 1 and 2 clinical trials for pancreatic and colorectal cancer.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: Bethesda, United States
Employees: 11
Open positions: None listed
Dealroom signal: 26.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biomarkers, Antibodies, Spinout, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Oct 2015	$50M	$200M	NantCell \| Nantworks	—
EARLY VCOther financing	Apr 2014	$800K	$3.2M	Undisclosed	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Precision Biologics website traffic

Latest recorded traffic for Precision Biologics is 1.2K monthly website visits, up 0% over the last three months. Precision Biologics's team grew 0% over the past year.

Latest monthly visits1.2K 3-month web change0% 1-year team growth0%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBiomXCustomized phage therapies to eradicate harmful bacteria in chronic diseases	Ness Ziona, Israel	Operational	30	$113M	$13M
FBFortitude BiomedicinesNext-generation biologics and antibody-drug conjugates for cancer	United States	Operational
NMNOBO MedicineBiomarker-driven targeted therapies for oncology and chronic diseases	Seoul, South Korea	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
MEMEDICStreamlined cancer drug target discovery/validation by CRISPR functional genomics in cancer organoid models at scale	Mountain View, United States	Operational
IMImmuneedDeveloping a new generation of prostate cancer vaccines, based on activation of the body's own immune system	Uppsala kommun, Sweden	Acquired
TATurbine AISimulation-driven drug discovery company delivering population targeted cancer therapies	Budapest, Hungary	Operational
GTGalecto \| Damora TherapeuticsBiotechnology for mutant calreticulin-driven hematologic disorders, formerly known as Galecto	Copenhagen, Denmark	Operational